Merck execs struggle with growing uncertainty over late-stage R&D

By John Carroll Merck is in a world of hurt. The pharma giant managed to spook several analysts with the news that its osteoporosis drug odanacatib would be held back from regulators ...

Gilead racks up 18% sales hike as HIV meds keep growing

By Tracy Staton  Cue Big Pharma envy. Gilead Sciences ($GILD) posted an impressive 18% growth in fourth-quarter revenues, to a street-beating $2.59 billion. Sales grew even in Europe, ...

While BMS shops emerging markets brands, GSK wraps $900M buy in India

By Tracy Staton  Two consumer health deals, two Big Pharma approaches toward emerging markets. While Bristol-Myers Squibb ($BMY) is looking around for buyers for a portfolio of consumer ...

Disappointed shareholder Fidelity agitates for Endo sale

By Tracy Staton If Endo Health Solutions ($ENDP) sells, you can credit–or blame–Fidelity Investments. That’s according to Bloomberg sources, who say Fidelity is ...

FDA approves generic Doxil to combat drug shortage

By Alison Bryant It can pay to play with the FDA when it needs help with drug shortages. In a push to ease a months-long shortage of Johnson & Johnson’s ($JNJ) cancer ...

Layoffs, check. Now, on to hiring–and talent’s scarce

Industry may need fewer folks in sales, but more in regulatory, bioinformatics By Tracy Staton Pharma execs say they’re plagued by another shortage. But in this case, it’s ...

Medtronic grabs CE mark for next-gen ICD

By Damian Garde Medtronic ($MDT) snagged CE mark approval for its Evera line of ICDs, planning to launch devices the company says offer increased longevity, lower risk of shock and ...

The flu + broader global Dx sales boost Becton Dickinson’s Q1

By Mark Hollmer Becton Dickinson ($BDX) rebounded from a sluggish end to its 2012 fiscal year with a solid increase in 2013 first quarter revenue. International expansion for its diagnostics ...

Novian Health grabs $11M for breast cancer laser treatment test

By Mark Hollmer Novian Health pulled in an $11 million Series A funding round that will help fuel an international clinical trial testing its laser therapy breast cancer treatment. The ...

Life Tech: ‘All ideas on the table’ amid sale rumors

By Damian Garde Life Technologies ($LIFE) says its keeping its options wide open during a strategic review, considering selling itself as analysts predict the sequencing giant’s ...

FDA approves generic version of cancer drug Doxil

* FDA approves Sun Pharma Global FZE’s generic Doxil * First generic version to be approved by FDA * Approval expected to relieve shortages By Toni Clarke (Reuters) – U.S. ...

A Closer Look At Keryx Biopharmaceuticals’ Phase III Result Announcement

By InvestorR Keryx (KERX) announced topline results from its Phase III study of Zerenex, a patented formulation of ferric citrate it has licensed, for the treatment of hyperphosphatemia ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS